drugset / Trial / NCT01290042

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

NCT01290042 ↗

Phase 1 Completed 43 enrolled Amgen
RandomizedSingle-groupQuadruple-blindTreatment

Summary

To assess the safety and tolerability of multiple subcutaneous doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.

Timeline

Start
2011-02
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abrilumab Monoclonal antibody — Subcutaneous